Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 10/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31414932 | 0.91 | FABP4 (0.45) | FABP4FABP5ERAP1BDKRB1 | |
| SCHEMBL31414901 | 0.83 | BDKRB1 (0.39) | SLC22A2BDKRB1 | |
| SCHEMBL31414906 | 0.77 | FABP4 (0.45) | FABP4FABP5 | |
| SCHEMBL31414847 | 0.77 | FABP4 (0.45) | FABP4FABP5 | |
| SCHEMBL31414870 | 0.76 | BDKRB1 (0.42) | BDKRB1 | |
| SCHEMBL31414899 | 0.73 | BDKRB1 (0.38) | BDKRB1 | |
| SCHEMBL25706639 | 0.66 | CES2 (0.38) | SLC22A2CES2CES1RECQL | |
| SCHEMBL6239390 | 0.66 | FABP4 (0.60) | FABP4FABP5 | |
| SCHEMBL1740298 | 0.62 | KCNK3 (0.46) | FABP4ERAP1CES2CES1 | |
| SCHEMBL16372472 | 0.61 | CES2 (0.43) | CES2CES1BDKRB1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026745-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | MIRUM PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026745-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B13, HSD17B1, HSD17B3 | FABP4 1043/4885SLC22A2 1162/4885FABP5 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.